Mersana Therapeutics, a biopharmaceutical company developing its Fleximer® antibody-drug conjugate (ADC) platform, today announced the creation of a Scientific Advisory Board (SAB) comprised of five recognized leaders in the fields of oncology and antibody therapeutics. The SAB will provide critical strategic and scientific insight as the company advances its pipeline of next-generation ADCs.
Help employers find you! Check out all the jobs and post your resume.
